Trastuzumab conjugated PEG – Fe3O4@Au nanoparticle as an MRI biocompatible nano-contrast agent
Source abstract
Abstract
A novel targeted tumor contrast agent in magnetic resonance imaging (MRI) was synthesized based on Fe3O4@Au nanoparticle coated with polyethylene glycol (PEG) and decorated with trastuzumab (TZ). The prepared system was fully characterized, and relaxivity, cytotoxicity, colloidal stability, blood compatibility, in vitro cell targeting ability, cytotoxicity, and in vivo MR contrast enhancement were evaluated. The developed system with a size of about 30 nm exhibited excellent stability, blood compatibility, proper relaxivity, negligible in vitro cytotoxicity, and suitable in vivo negative contrast enhancement. Appropriate negative signal enhancement in MRI confirmed the efficiency of the system to be suggested as an encouraging candidate for accurate cancer diagnosis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Lanthanide and Transition Metal Complexes · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Medical Radiation Sciences Research Team, Tabriz University of Medical Sciences, Tabriz, Iran
Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Funding
Tabriz University of Medical Sciences
References (40)
Show source-provided references
1. 10.1016/j.addr.2005.01.02410.1016/j.addr.2005.01.024 ↗
2. 10.1002/adma.20080236610.1002/adma.200802366 ↗
3. 10.1016/j.carbpol.2020.11726210.1016/j.carbpol.2020.117262 ↗
4. 10.1021/am101235810.1021/am1012358 ↗
5. 10.1007/s11051-018-4376-210.1007/s11051-018-4376-2 ↗
6. 10.1016/j.biomaterials.2014.10.05210.1016/j.biomaterials.2014.10.052 ↗
7. 10.1039/C7TB00382J10.1039/C7TB00382J ↗
8. T M. · J. Biomed. Phys. Eng · 2020 · 10 · 25
9. 10.1080/1061186X.2019.170318810.1080/1061186X.2019.1703188 ↗
10. 10.1055/a-0647-176510.1055/a-0647-1765 ↗
11. 10.1002/aoc.561410.1002/aoc.5614 ↗
12. 10.1016/j.msec.2018.07.01910.1016/j.msec.2018.07.019 ↗
13. 10.1016/j.jddst.2018.01.01110.1016/j.jddst.2018.01.011 ↗
14. 10.1016/j.jcis.2019.08.04610.1016/j.jcis.2019.08.046 ↗
15. 10.1016/j.bioorg.2021.10521110.1016/j.bioorg.2021.105211 ↗
16. 10.1049/iet-nbt.2018.536010.1049/iet-nbt.2018.5360 ↗
17. 10.1038/s41598-017-12150-810.1038/s41598-017-12150-8 ↗
18. Babaye Abdollahi B. · Adv. Pharm. Bull. · 2021 · 11 · 212
19. 10.1016/j.ijpharm.2017.02.00810.1016/j.ijpharm.2017.02.008 ↗
20. 10.1016/j.breast.2017.03.00910.1016/j.breast.2017.03.009 ↗
21. 10.1002/med.2134510.1002/med.21345 ↗
22. 10.1021/am302883m10.1021/am302883m ↗
23. 10.3390/nano810081010.3390/nano8100810 ↗
24. 10.1007/s11051-015-3097-z10.1007/s11051-015-3097-z ↗
25. 10.3390/nano904063210.3390/nano9040632 ↗
26. 10.1016/j.bios.2018.06.01010.1016/j.bios.2018.06.010 ↗
27. 10.1021/cm201297x10.1021/cm201297x ↗
28. 10.1016/j.ijpharm.2016.05.04610.1016/j.ijpharm.2016.05.046 ↗
29. 10.1039/C8NJ03310B10.1039/C8NJ03310B ↗
30. 10.1038/srep4477010.1038/srep44770 ↗
31. Jain S. · Radiother. Oncol · 2010 · 96 · S26
32. 10.1016/j.biomaterials.2015.05.00310.1016/j.biomaterials.2015.05.003 ↗
33. 10.1208/s12249-020-01743-810.1208/s12249-020-01743-8 ↗
34. 10.1016/j.biomaterials.2013.11.03210.1016/j.biomaterials.2013.11.032 ↗
35. 10.1016/B978-0-08-101925-2.00002-410.1016/B978-0-08-101925-2.00002-4 ↗
36. 10.4155/tde.13.610.4155/tde.13.6 ↗
37. 10.1002/ange.20080246910.1002/ange.200802469 ↗
38. 10.1016/j.biomaterials.2012.11.05410.1016/j.biomaterials.2012.11.054 ↗
39. 10.1021/acs.chemmater.6b0241310.1021/acs.chemmater.6b02413 ↗
40. Li L. · Drug Deliv. · 2016 · 23 · 1726